Ken Griffin Roivant Sciences Ltd. Transaction History

Citadel Advisors LLC

$505 Billion
Q3 2024

A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Roivant Sciences Ltd. stock. As of the latest transaction made, Citadel Advisors LLC holds 51,800 shares of ROIV stock, worth $621,600. This represents 0.0% of its overall portfolio holdings.

Number of Shares

51,800

Previous 69,400 25.36%

Holding current value

$621,600

Previous $733,000 18.55%

% of portfolio

0.0%

Previous 0.0%

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$10.17 - $12.5 $40.7 Million - $50.1 Million	4,004,146 Added 208.11%	5,928,183 $68.4 Million
Q2 2024 Aug 14, 2024	SELL	$10.36 - $11.74 $12.6 Million - $14.3 Million	-1,215,542 Reduced 38.72%	1,924,037 $20.3 Million
Q1 2024 May 15, 2024	SELL	$9.87 - $11.8 $3.38 Million - $4.04 Million	-342,124 Reduced 9.83%	3,139,579 $33.1 Million
Q4 2023 Feb 14, 2024	BUY	$8.38 - $11.58 $28.1 Million - $38.9 Million	3,355,500 Added 2658.81%	3,481,703 $39.1 Million
Q3 2023 Nov 14, 2023	BUY	$9.76 - $13.19 $985,994 - $1.33 Million	101,024 Added 401.22%	126,203 $1.47 Million
Q2 2023 Aug 14, 2023	SELL	$7.09 - $10.08 $9.77 Million - $13.9 Million	-1,378,661 Reduced 98.21%	25,179 $253,000
Q1 2023 May 15, 2023	BUY	$6.92 - $9.98 $3.74 Million - $5.39 Million	539,869 Added 62.49%	1,403,840 $10.4 Million
Q4 2022 Feb 14, 2023	SELL	$3.36 - $7.99 $1.92 Million - $4.55 Million	-570,054 Reduced 39.75%	863,971 $6.9 Million
Q3 2022 Nov 14, 2022	BUY	$0.51 - $4.84 $635,804 - $6.03 Million	1,246,676 Added 665.43%	1,434,025 $4.62 Million

Others Institutions Holding ROIV

# of Institutions

310

Shares Held

507M

Call Options Held

1.26M

Put Options Held

2.52M

View Full List

About Roivant Sciences Ltd.

Ticker ROIV
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 704,382,976
Market Cap $8.45B
Description
Roivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines. The company develops product candidates for the treatment of various therapeutics, including solid tumors, sickle cell diseases, hypophosphatasia, oncologic malignancies, psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne...

More about ROIV

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account